Jian Lin
Fortuna: 154 814 $ al 31/07/2026
Fortuna: 154 814 $ al 31/07/2026
Jian Lin is currently Director at Remegen Biosciences, Inc. and Director at Ruimeijing Beijing Pharmaceutical Technology Co. Ltd. Formerly, Mr. Lin was Executive Director at RemeGen Co., Ltd. from 2020 to 2026.
Mr. Lin completed an undergraduate degree at Harbin University of Commerce in 1982.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
REMEGEN CO. LTD. CLASS H 0,01 % | 16/06/2026 | 14.850 ( 0,01 % ) | 154 814 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Remegen Biosciences, Inc.
Remegen Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biopharmaceutical therapies for cancer & autoimmune diseases | Director/Miembro de la Junta | - |
Ruimeijing Beijing Pharmaceutical Technology Co. Ltd. | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| REMEGEN CO., LTD. | Director/Miembro de la Junta | 16/06/2026 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Harbin University of Commerce
Harbin University of Commerce Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RemeGen Co., Ltd.
RemeGen Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures cancer drugs | Health Technology |
Remegen Biosciences, Inc.
Remegen Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biopharmaceutical therapies for cancer & autoimmune diseases | Commercial Services |
Ruimeijing Beijing Pharmaceutical Technology Co. Ltd. |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.